Main Facts: A Landmark Shift in Islet Cell Transplantation
n
In a historic milestone for regenerative medicine and autoimmune research, a new clinical trial has officially launched to evaluate the efficacy of tegoprubart—an investigational monoclonal antibody developed by Eledon Pharmaceuticals—in combination with islet cell transplantation. This trial specifically targets individuals living with both Type 1 Diabetes (T1D) and Chronic Kidney Disease (CKD), a patient population that has historically been excluded from such cutting-edge therapies due to the nephrotoxic nature of standard immunosuppressive drugs.
n
The trial, funded by a significant $8.5 million grant from Breakthrough T1D (formerly JDRF), represents a dual-front assault on the complications of diabetes. For the first time in the history of islet cell therapy, patients with reduced kidney function are eligible to participate in a study aimed at restoring endogenous insulin production. The announcement comes with the news that the first participant has already been successfully enrolled and has received their islet cell transplant at the University of Chicago.
n
Tegoprubart functions as a targeted immune therapy designed to prevent the rejection of transplanted insulin-producing islet cells without the devastating side effects associated with traditional "calcineurin inhibitors" (CNIs). By utilizing this novel approach, researchers hope to provide a functional cure for T1D while preserving—and potentially protecting—the fragile kidney function of participants.
n
Chronology: From the Edmonton Protocol to Targeted Immunotherapy
n
The journey toward this clinical trial began decades ago with the development of the "Edmonton Protocol" in the late 1990s, which proved that islet cell transplantation could lead to insulin independence. However, the protocol relied heavily on a cocktail of immunosuppressants, most notably tacrolimus. While effective at preventing immediate organ rejection, tacrolimus is notorious for its "nephrotoxicity"—it is essentially poisonous to the kidneys over long-term use.
n
Because many people with long-standing T1D eventually develop CKD, the medical community faced a cruel paradox: the very patients who most needed a transplant to stabilize their blood sugar were the ones whose kidneys could not survive the drugs required to maintain that transplant. Consequently, for the last twenty years, islet cell transplantation remained a "last resort" reserved only for those with perfect kidney function or those undergoing a simultaneous kidney-pancreas transplant.
n
The timeline shifted significantly with the emergence of tegoprubart (formerly known as AT-1501). Unlike broad-spectrum immunosuppressants that shut down large portions of the immune system, tegoprubart is a humanized monoclonal antibody that targets the CD40L (CD154) pathway. This pathway is critical for the "co-stimulation" of T-cells; by blocking it, the drug prevents the immune system from attacking the new islet cells while leaving other protective immune functions more intact.
n
In recent years, Eledon Pharmaceuticals initiated a Breakthrough T1D-funded trial for tegoprubart in T1D patients suffering from severe hypoglycemic unawareness but who had healthy kidneys. The results were transformative: all 12 participants in the initial cohort achieved insulin independence, living free from injections with a remarkably clean safety profile. Building on this success, the current trial marks the logical and necessary expansion into the "high-risk" CKD population, aiming to prove that tegoprubart is safe enough for those whose renal health is already compromised.
n
Supporting Data: The Science of Islet Survival and Renal Protection
n
The clinical necessity of this trial is underscored by the prevalence of diabetic nephropathy. Statistics show that approximately 30% to 40% of all T1D patients will eventually develop some degree of Chronic Kidney Disease. For these individuals, the management of blood glucose becomes a tightrope walk; failing kidneys struggle to process insulin, leading to unpredictable and often life-threatening "lows" (hypoglycemia).
n
The Problem with Calcineurin Inhibitors (CNIs)
n
Standard immunosuppression involves CNIs like tacrolimus, which work by inhibiting the phosphatase activity of calcineurin. While this prevents T-cell activation, it also causes:
n
- n
- Vasoconstriction: It narrows the blood vessels in the kidneys, reducing filtration rates.
- Islet Toxicity: Ironically, tacrolimus has been shown to be toxic to the very beta cells being transplanted, often shortening the lifespan of the graft.
- Metabolic Side Effects: It can cause "new-onset diabetes after transplantation" (NODAT) in non-diabetic patients, making it counterproductive for T1D patients.
n
n
n
n
The Tegoprubart Alternative
n
Tegoprubart’s mechanism of action—targeting the CD40L/CD40 interaction—offers a "CNI-free" regimen. Data from preclinical non-human primate studies and the ongoing T1D trials suggest that this approach:
n
- n
- Maintains superior graft function compared to tacrolimus.
- Does not induce the high blood pressure or glucose intolerance common with steroids and CNIs.
- Shows zero evidence of nephrotoxicity, making it a viable candidate for patients with low Glomerular Filtration Rates (GFR).
n
n
n
n
Trial Design and Metrics
n
The current multi-center trial is enrolling up to 10 participants at the University of Chicago and the University of Miami. The primary endpoint of the study is the percentage of participants who, one year after the transplant, meet the "triple crown" of T1D success:
n
- n
- Insulin Independence: No longer requiring daily insulin injections.
- Glycemic Control: Maintaining an HbA1c level of less than 7.0%.
- Safety: Zero severe hypoglycemic episodes, as verified by Continuous Glucose Monitoring (CGM) data.
n
Official Responses: A Unified Vision for a Cure
The launch of this trial has drawn praise from leading figures in the diabetes research community, who view it as a pivotal step in the "Project ACT" initiative—a strategic roadmap to accelerate cell therapies.
Esther Latres, Ph.D., Senior Vice President of Research at Breakthrough T1D, emphasized the organizational commitment to expanding access. “Advancing promising islet cell research that is a next step toward durable and scalable cures for type 1 diabetes is a key priority for Breakthrough T1D," Dr. Latres stated. "We’re proud to support this trial that expands cell therapy research and access to people living with T1D and chronic kidney disease for the first time.”
The University of Chicago Medicine, home to one of the world’s leading islet transplant programs, is spearheading the clinical execution. Lead investigators have noted that the ability to offer a CNI-free protocol is a "game-changer" for patient recruitment, as many T1D patients with early-stage kidney issues were previously told they had no options for cell replacement therapy.
Eledon Pharmaceuticals, which is also a portfolio company of the T1D Fund (the venture philanthropy arm of Breakthrough T1D), has expressed confidence that this trial will validate tegoprubart as the new "gold standard" for transplant induction and maintenance. By proving the drug’s safety in the CKD population, Eledon aims to clear the path for tegoprubart to be used in broader organ transplantation, including kidney and liver transplants.
Implications: Paving the Way for Scalable, Universal Cures
The implications of this trial extend far beyond the 10 initial participants. If successful, this study will dismantle one of the most significant "eligibility barriers" in the field of diabetes.
Expanding the Patient Pool
Historically, islet transplantation has been a niche procedure due to the risks of the medication. By proving that a milder, targeted therapy can protect both the graft and the kidneys, the procedure could move from a "last-ditch effort" to a standard-of-care intervention for a much larger portion of the T1D population.
The Road to "Immuno-Evasion"
This trial is a crucial bridge in the broader "Project ACT" roadmap. The ultimate goal of Breakthrough T1D and its partners is to reach a future where islet cells can be transplanted with zero systemic immunosuppression. This might be achieved through "encapsulation" (putting cells in a protective pouch) or gene-editing (creating "stealth" cells that the immune system cannot see). However, until those technologies are perfected, tegoprubart represents the most advanced "middle ground"—a way to minimize the burden of immunosuppression to the point where the benefits of a transplant far outweigh the risks for the average patient.
Economic and Quality of Life Impact
The financial burden of T1D and CKD is astronomical, involving the costs of insulin, CGM supplies, and potentially dialysis or kidney transplants. A "functional cure"—where a patient produces their own insulin and avoids kidney failure—would represent a massive shift in the economics of chronic disease management. More importantly, it offers patients a life free from the constant fear of hypoglycemic episodes and the grueling routine of multiple daily injections.
As the first participant in this trial begins their journey toward insulin independence, the medical community watches with cautious optimism. This is more than just a test of a new drug; it is a test of a new philosophy in medicine—one that refuses to accept that the "cure" must be as toxic as the disease. Through the collaboration of non-profits like Breakthrough T1D, innovative biotech firms like Eledon, and world-class academic institutions, the dream of a scalable, safe, and universal cure for Type 1 Diabetes has never been closer to reality.
